Go offline with the Player FM app!
A Visionary Approach to Uveitis: Tarsier Pharma’s Disruptive Innovation
Manage episode 466661425 series 2286865
In this OIS Podcast episode, host Dr. Robert Rothman sits down with Daphne Haim-Langford, PhD, Founder & CEO of Tarsier Pharma, and Ashley Kline, Chief Commercial Officer, to discuss their groundbreaking approach to uveitis treatment.
Tarsier’s lead candidate, TRS01, is a first-in-class bio-inspired therapy designed to control inflammation without raising intraocular pressure, a major complication of steroid treatments. With a unique mechanism of action that modulates macrophages and reduces inflammation, this novel drug has the potential to redefine uveitis and glaucoma care.
In this episode, you’ll learn:
🔹 How Tarsier’s bio-inspired molecule is changing the game in ophthalmology.
🔹 Why steroids, despite being the standard of care, can be problematic for uveitis patients.
🔹 The challenges of scaling manufacturing and securing regulatory approval for novel ophthalmic treatments.
🔹 Insights from Ashley Kline on the commercial strategy for launching Tarsier’s therapy.
🔹 How Dr. Rothman sees this innovation reshaping ophthalmology and glaucoma treatment.
🎧 Tune in to hear how Tarsier Pharma is working to bring a safer, more effective treatment to market! Subscribe to the OIS Podcast today!
421 episodes
Manage episode 466661425 series 2286865
In this OIS Podcast episode, host Dr. Robert Rothman sits down with Daphne Haim-Langford, PhD, Founder & CEO of Tarsier Pharma, and Ashley Kline, Chief Commercial Officer, to discuss their groundbreaking approach to uveitis treatment.
Tarsier’s lead candidate, TRS01, is a first-in-class bio-inspired therapy designed to control inflammation without raising intraocular pressure, a major complication of steroid treatments. With a unique mechanism of action that modulates macrophages and reduces inflammation, this novel drug has the potential to redefine uveitis and glaucoma care.
In this episode, you’ll learn:
🔹 How Tarsier’s bio-inspired molecule is changing the game in ophthalmology.
🔹 Why steroids, despite being the standard of care, can be problematic for uveitis patients.
🔹 The challenges of scaling manufacturing and securing regulatory approval for novel ophthalmic treatments.
🔹 Insights from Ashley Kline on the commercial strategy for launching Tarsier’s therapy.
🔹 How Dr. Rothman sees this innovation reshaping ophthalmology and glaucoma treatment.
🎧 Tune in to hear how Tarsier Pharma is working to bring a safer, more effective treatment to market! Subscribe to the OIS Podcast today!
421 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.